$ACT Recent News 10 S&P 500 companies with the fastest

New Post Public Reply Private Reply Replies (0) Message Board

Nov 11, 2014 at 10:00 AM

$ACT Recent News

10 S&P 500 companies with the fastest revenue growth 8:28 a.m. Today - Philip van Doorn
Ackman urges Allergan to open sale process, negotiate 10:33 a.m. Nov. 7, 2014 - Chelsey Dulaney
Actavis sales surge, exceed forecasts 7:51 a.m. Nov. 5, 2014 - MarketWatch.com
Media, consumer-based company earnings to test stock rally 4:30 a.m. Nov. 2, 2014 - Wallace Witkowski
Pfizer sales fall less than expected 7:34 a.m. Oct. 28, 2014 - MarketWatch.com
3 stocks Ken Fisher likes 11:09 a.m. Oct. 21, 2014 - Insider Monkey
In focus: Volatility ramps up 5:35 p.m. Oct. 8, 2014 - Lawrence G. McMillan
Small-cap buckling and trap doors could make for a brutal earnings season 6:07 a.m. Oct. 8, 2014 - Shawn Langlois
Valeant to boost Allergan bid by $15 a share: report 5:48 p.m. Oct. 7, 2014 - Russ Britt
Actavis agrees to acquire Durata Therapeutics 8:44 a.m. Oct. 6, 2014 - Tess Stynes
Pharma love triangle is a win, win, win for investors 1:11 p.m. Oct. 2, 2014 - The Trading Deck
In focus: Finally, a breakdown 7:40 p.m. Oct. 1, 2014 - Lawrence G. McMillan
In focus: Back in the trading range 2:26 p.m. Sept. 24, 2014 - Lawrence G. McMillan
Actavis reportedly in talks to buy Salix Pharma 11:51 a.m. Sept. 24, 2014 - Russ Britt
Actavis's Salix play undermines Allergan defense 11:43 a.m. Sept. 24, 2014 - Russ Britt
Actavis reportedly in talks to buy Salix Pharma 11:42 a.m. Sept. 24, 2014 - Russ Britt
Actavis shares rise on report of Pfizer approach 2:49 p.m. Sept. 23, 2014 - Ciara Linnane
Botox maker Allergan rejected Actavis takeover bid 6:18 p.m. Sept. 22, 2014 - Jonathan D. Rockoff
In focus: Market giving mixed signals 7:02 p.m. Sept. 17, 2014 - Lawrence G. McMillan
DEA restricts narcotic pain-drug prescriptions 7:27 p.m. Aug. 21, 2014 - Louise Radnofsky

Actavis Says 'Let's Make A Deal' 17 min ago - Seeking Alpha
Actavis (ACT) Upgraded From Hold to Buy 54 min ago - TheStreet.com
A Look at the Top Five Medical Stocks Held in the Vanguard Portfolio 5:16 p.m. Nov. 9, 2014 - GuruFocus.com
Ackman Calls for Auction of Allergan 3:38 p.m. Nov. 7, 2014 - The Wall Street Journal Interactive Edition
3 Stocks Dragging In The Drugs Industry 12:06 p.m. Nov. 7, 2014 - TheStreet.com
Comparing America's 3 Largest Generic Drugs Companies 10:05 a.m. Nov. 7, 2014 - Seeking Alpha
Salix Shares Plunge on Accounting Revision 8:57 p.m. Nov. 6, 2014 - The Wall Street Journal Interactive Edition
Ironwood Pharmaceuticals' Q3 Loss Narrower than Expected - Analyst Blog 1:20 p.m. Nov. 6, 2014 - Zacks.com
Company News for November 06, 2014 - Corporate Summary 10:10 a.m. Nov. 6, 2014 - Zacks.com
How Billionaires Stack Up in Bill Ackman's Big Allergan Bid 9:25 a.m. Nov. 6, 2014 - TheStreet.com
Deutsche Bank’s U.S. Stock Selection Best Buy Ideas 7:43 a.m. Nov. 6, 2014 - 247WallSt.com
Jim Cramer's Top Stock Picks: LMT MPC ACT 6:00 a.m. Nov. 6, 2014 - TheStreet.com
Cramer's Mad Money - Actavis, What A Stock (11/5/14) 5:57 a.m. Nov. 6, 2014 - Seeking Alpha
2 Biotech Stocks to Buy After Earnings 5:45 a.m. Nov. 6, 2014 - InvestorPlace.com
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks 8:20 p.m. Nov. 5, 2014 - TheStreet.com
10-Q: ACTAVIS PLC 5:06 p.m. Nov. 5, 2014 - Edgar Online - (EDG = 10Q, 10K)
Actavis (ACT) Earnings Report: Q3 2014 Conference Call Transcript 2:10 p.m. Nov. 5, 2014 - TheStreet.com
3 IBD 50 Tech, Drug Stocks With Earnings Thursday 1:49 p.m. Nov. 5, 2014 - Investors Business Daily
Actavis' (ACT) CEO Brent Saunders on Q3 2014 Results - Earnings Call Transcript 1:29 p.m. Nov. 5, 2014 - Seeking Alpha
Actavis Beats Q3 Estimates As Buyout Talk Swirls 10:07 a.m. Nov. 5, 2014 - Investors Business Daily

Actavis Names Maria Teresa Hilado Chief Financial Officer 4:15 p.m. Nov. 10, 2014 - PR Newswire - PRF
Quarterly Financial Performance Reviews, Upcoming Events, and Medicare Plan Launch - Research Reports on Actavis, Celgene, UnitedHealth, Jazz and Endo 8:50 a.m. Nov. 10, 2014 - PR Newswire - PRF
Actavis Announces Planned Retirement of R. Todd Joyce in Early 2015 6:45 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 83% to $3.7 Billion in Third Quarter 2014; Non-GAAP EPS Increases 53% to $3.19 6:30 a.m. Nov. 5, 2014 - PR Newswire - PRF
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of Durata 4:15 p.m. Oct. 31, 2014 - PR Newswire - PRF
Actavis Confirms Appeals Court Upholds Lo Loestrin® Fe Patent 8:00 a.m. Oct. 23, 2014 - PR Newswire - PRF
New Medicare Plan, Clinical Study Results, ANDA Filing Confirmation, Strategic Collaboration, and Merger Termination - Research Reports on UnitedHealth, Celgene, Actavis, Bristol-Myers Squibb and Salix 9:10 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 8:30 a.m. Oct. 22, 2014 - PR Newswire - PRF
Pharma Stocks Technical Data - Allergan, Zoetis, Actavis, Avanir Pharma, and Mallinckrodt 8:40 a.m. Oct. 20, 2014 - PR Newswire - PRF
Actavis Confirms Generic Quillivant XR® Patent Challenge 8:00 a.m. Oct. 16, 2014 - PR Newswire - PRF
Acquisition, Market Activity, and Upcoming Events - Research Reports on Auxilium, Lakeland, Endo, Actavis and Celgene 8:30 a.m. Oct. 14, 2014 - PR Newswire - PRF
Ironwood and Actavis to Present Linaclotide Data at the American College of Gastroenterology 2014 Annual Scientific Meeting 8:00 a.m. Oct. 9, 2014 - BusinessWire - BZX
EQUITY ALERT: Rosen Law Firm Announces Investigation of Durata Therapeutics, Inc. Concerning its Proposed Sale to Actavis plc – DRTX 11:35 a.m. Oct. 6, 2014 - BusinessWire - BZX
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout 11:34 a.m. Oct. 6, 2014 - PR Newswire - PRF
Actavis to Acquire Durata Therapeutics, Inc. 8:00 a.m. Oct. 6, 2014 - PR Newswire - PRF
Regulatory Approvals, Lawsuits, Positive Study Results, Welfare Initiatives, and Technical Updates - Research Reports on Celgene, Actavis, Bristol-Myers Squibb, UnitedHealth and Vertex 9:20 a.m. Oct. 2, 2014 - PR Newswire - PRF
Supernus Sues Actavis for Infringement of Trokendi XR(R) Patents 7:30 a.m. Oct. 2, 2014 - GlobeNewswire
Actavis to Host Third Quarter 2014 Earnings Conference Call and Webcast 8:00 a.m. Sept. 30, 2014 - PR Newswire - PRF
Actavis Confirms Generic Butrans® Patent Challenge 4:05 p.m. Sept. 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kenneth Spells: Championing Education Leadership in 2026

Out there in Hoke County, you’ve got a man named Kenneth Spells shaking things up the way a strong leader should. Now, you know I’m not here to fluff up anyone’s feathers—especially in an arena as aching for reform as education. But credit where credit’s due, Spells picked up the ‘2026 Professional of the Year’ from The Inner Circle for a reason, and it’s...

Winter Prep: Home Safety Vital for Older Adults

Cold Weather is All About Precaution It ain't the first day at the fair when you realize winter's sneaking up, and with it, the looming concern of older family members hunkering down indoors. Executive Home Care's calling out, saying it straight: if you've got seniors in your midst, now's the time to batten down the hatches. The winter months can turn into a slippery...

ITG Names Juliette Aiken CMO to Boost Storyteq's Reach

How do you put the throttle down on AI-driven content in a market that’s gasping for more? You bring in a heavyweight. Storyteq, the brainchild platform of Inspired Thinking Group (ITG), has roped in Juliette Aiken as their new Chief Marketing Officer. A veteran of the field, Juliette is tasked with propelling Storyteq from strong performer to an unbeatable force. New...

SEC Enforcement Lags: FY26 Sees Subdued Activity Surge

Parsing the Numbers: SEC's FY26 Performance It's like watching paint dry in the middle of a trading frenzy; the SEC's enforcement actions in FY26 were nothing to write home about. A mere 308 enforcement actions graced the ledger, a stunning 57% dive below the average from FY18 through FY25. When you think about the established numbers, it feels like the SEC decided to...

Shadeform Debuts Flex VMs, Revolutionizing GPU Utilization

GPU Utilization Gets a New Spin with Flex VMs Folks, listen up: Shadeform just fired up something slick with its new Flex VMs. And, let me tell you, in today's market where GPU capacity is vanishing faster than free hotcakes on a Sunday morning, this might well be a game changer. Shadeform’s the name to remember, teaming up data center veterans with peeps who need to...

AppLovin Faces Lawsuit Over AI Claims: Investor Alert

AI Promises or Pipedreams? AppLovin Corporation finds itself in a bit of hot water, and if you've got skin in this game, you've probably felt the heat. So, what's stirring the pot? A class action lawsuit against AppLovin (NASDAQ: APP) for allegedly pulling the wool over investors' eyes with overstated claims about their generative AI tool. Class Action: Weighing the...

York Space Systems Faces Securities Law Class Action

Unexpected Turbulence at York Space Systems Just when you thought things might be smooth sailing, York Space Systems (NYSE: YSS) finds itself on the hot seat. This fledgling aerospace player is now wrangling with a class action lawsuit for allegedly breaking federal securities laws. Call it a wake-up call from DJS Law Group encouraging investors who've had their fingers...

S?LACE Boats Unveils First Catamaran, the 41CT

Setting a New Course with the 41CT Picture this: a company known for pushing the envelope does it again, but this time, they aren't just elbowing their way into the catamaran market—they're redefining it. S?LACE Boats has unveiled their all-new 41CT center console catamaran. Not just another addition, it's practically a game-changer for anyone passionate about offshore...

Millrose Investors Face Unveiling of Financial Missteps

A Cold Shower for Millrose Properties' Investors Investing in Millrose Properties, Inc. (NYSE: MRP) didn't quite pan out as some folks hoped. On the heels of Hunterbrook's report about dubious deals, the Company's stock tumbled 8.53%, smacking investors with a not-so-gentle reminder of market realities. Sure, stocks can dip and dive like a rollercoaster, but when it...

Goodyear Preps for Q3 2026 Earnings Report, Call

Gearing Up for Goodyear's Latest Financials Here we go, folks—Goodyear Tire & Rubber Company is ready to roll out their third quarter's financial results for 2026. Come November 4, after the market goes to sleep, the big wigs at Goodyear will toss out the numbers. We’ll all get the chance to dig into the figures that they’ll slap on their investor website. Then,...